Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Oral Oncol. 2019 Feb 1;90:38–44. doi: 10.1016/j.oraloncology.2019.01.017

Figure 6 – Ionizing radiation variably alters cetuximab or avelumab-enhanced cytolysis of HNSCC cells by haNKs.

Figure 6 –

(A) Quantification of percent loss of cell index relative to control (no haNKs) 24 hours after the addition of haNKs. HNSCC cells with or without prior exposure to a single dose of 8Gy IR were plated and allowed to gain impedance overnight before the addition of haNKs with or without avelumab or cetuximab (1 μg/mL). (B) HNSCC cells were assessed for changes in PD-L1 and EGFR expression 24 hours after a single dose of 8Gy IR by flow cytometry. Representative results from one of at least two independent assays shown, each performed in at least technical triplicate. *, p<0.05; **, p<0.01; student’s t-test.